WuXi PharmaTech Beats on Both Top and Bottom Lines
byNov 13th 2012 1:02PM
WuXi PharmaTech (NYS: WX) reported earnings on May 13. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), WuXi PharmaTech beat slightly on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded. Non-GAAP earnings per share grew. GAAP earnings per share increased.
Gross margins grew, operating margins dropped, net margins shrank.
WuXi PharmaTech logged revenue of $131.9 million. The six analysts polled by S&P Capital IQ foresaw a top line of $130.5 million on the same basis. GAAP reported sales were 12% higher than the prior-year quarter's $118.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.35. The five earnings estimates compiled by S&P Capital IQ forecast $0.32 per share. Non-GAAP EPS of $0.35 for Q1 were 6.1% higher than the prior-year quarter's $0.33 per share. GAAP EPS of $0.30 for Q1 were 3.4% higher than the prior-year quarter's $0.29 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 36.0%, 50 basis points better than the prior-year quarter. Operating margin was 17.4%, 10 basis points worse than the prior-year quarter. Net margin was 16.5%, 130 basis points worse than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $142.3 million. On the bottom line, the average EPS estimate is $0.37.
Next year's average estimate for revenue is $572.8 million. The average EPS estimate is $1.49.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 326 members out of 346 rating the stock outperform, and 20 members rating it underperform. Among 76 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 71 give WuXi PharmaTech a green thumbs-up, and five give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on WuXi PharmaTech is outperform, with an average price target of $20.34.
Looking for alternatives to WuXi PharmaTech? It takes more than great companies to build a fortune for the future. Learn the basic financial habits of millionaires next door and get focused stock ideas in our free report, "3 Stocks That Will Help You Retire Rich." Click here for instant access to this free report.
- Add WuXi PharmaTech to My Watchlist.
The article WuXi PharmaTech Beats on Both Top and Bottom Lines originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.